New antibody aims to unlock immune attack on Hard-to-Treat cancers
NCT ID NCT04773951
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental antibody called JS004, which targets a protein on immune cells called BTLA, to see if it can help the immune system fight advanced solid tumors like melanoma, kidney cancer, and bladder cancer. The study includes JS004 alone or combined with another immunotherapy drug, Toripalimab. The main goals are to check safety, find the best dose, and get an early look at whether the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS004 (a BTLA-targeting antibody) and Toripalimab
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with a small number of participants, so the treatment may not prove effective or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
-
First Hospital of Jilin University
Changchun, Jilin, China
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
-
Run Run Shaw Hospital affiliated to Zhejiang University Medical College
Hangzhou, Zhejiang, China
-
Tumor Hospital affiliated to Harbin Medical University
Harbin, Heilongjiang, China
-
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.